<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01958190</url>
  </required_header>
  <id_info>
    <org_study_id>LOL-III-1</org_study_id>
    <nct_id>NCT01958190</nct_id>
  </id_info>
  <brief_title>Study Comparing in Livertransplantation Recipients With Tacrolimus Alone Versus Tacrolimus&amp;Sirolimus</brief_title>
  <official_title>A Multicenter Randomized in Primary Livertransplantation Comparing Longterm Renal Function in Recipients Treated With Tacrolimus Alone and Recipients Treated With a Combination Tacrolimus and Sirolimus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Foundation for Liver Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Foundation for Liver Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study we compare long term renal function in liver transplantation recipients treated&#xD;
      with standard dose extended-release tacrolimus alone and recipients treated with a&#xD;
      combination of low dose extended-release tacrolimus and low dose sirolimus. The hypothesis is&#xD;
      that the patients treated with the combination have better long term renal function than the&#xD;
      patients treated with standard dose tacrolimus alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the effectiveness and safety of concentration controlled combination of once&#xD;
      daily dosed low-dose sirolimus (trough levels: 3-5 ng/ml) and extended-release tacrolimus&#xD;
      (trough levels:3-5 ng/ml), in order to provide superior renal function while maintaining&#xD;
      comparable rates of patient and graft survival, compared to concentration controlled once -&#xD;
      daily extended release tacrolimus (trough levels: 5-10 ng/ml) at 12, 24 and 36 months&#xD;
      post-transplant. Moreover, to compare the incidence of de novo malignancy, the quality of&#xD;
      life, fatigue and side effects between both treatment arms.&#xD;
&#xD;
      2.1 Primary objectives: To evaluate the effectiveness and safety of concentration controlled&#xD;
      combination of low-dose sirolimus (trough levels: 3-5 ng/ml) and extended-release tacrolimus&#xD;
      (trough levels: 3-5 ng/ml), in order to provide superior renal function while maintaining&#xD;
      comparable rates of patient and graft survival, compared to concentration controlled once -&#xD;
      daily extended release tacrolimus (trough levels:-10 ng/ml) control at 12, 24 and 36 months&#xD;
      post-transplant.&#xD;
&#xD;
      2.2. Secondary objectives:&#xD;
&#xD;
        -  To compare the incidence of de novo and recurrence of cancer between study arm and&#xD;
           control arm at 36 months.&#xD;
&#xD;
        -  To compare the incidence and severity of biopsy proven acute rejection between study arm&#xD;
           and control arm at 12, 24 and 36 months.&#xD;
&#xD;
        -  To evaluate renal function at 12, 24 and 36 months (calculated GFR).&#xD;
&#xD;
        -  To evaluate the development of new onset diabetes mellitus at 12, 24 and 36 months post&#xD;
           transplant&#xD;
&#xD;
        -  To evaluate the prevalence of CNI side effects at 12, 24 and 36 months&#xD;
&#xD;
        -  To evaluate quality of life (Eq5D) and fatigue severity score at 12, 24 and 36 months&#xD;
&#xD;
        -  To evaluate the percentage of patients on combination tacrolimus and sirolimus and&#xD;
           converted back to tacrolimus mono-therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 7, 2011</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Actual">May 20, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Renal function</measure>
    <time_frame>3 years</time_frame>
    <description>Percentage of patients with cGFR &lt; 60ml/min</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Malignancies</measure>
    <time_frame>3 years</time_frame>
    <description>number of de novo malignancies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diabetes Mellitus</measure>
    <time_frame>3 years</time_frame>
    <description>Incidence of De novo diabetes mellitus</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">196</enrollment>
  <condition>Liver Disease</condition>
  <arm_group>
    <arm_group_label>Tacrolimus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient received standard-dose of Tracrolimus Advagraf (5-10 ng/ml) and 7.5 mg prednison; lower or discontinue steroids after day 180 at the discretion of the treating physician</description>
  </arm_group>
  <arm_group>
    <arm_group_label>combination Tacrolimus and Sirolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive combination of low-dose extended release Tacrolimus and low-dose Sirolimus</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus and Sirolimus</intervention_name>
    <description>Arm 1 once daily combination therapy of normal dosed extended-release tacrolimus and prednisone for 3 months and monotherapy once daily extended-release tacrolimus thereafter up to 3 years after liver transplantation.&#xD;
Arm 2 once daily combination therapy of low doses sirolimus and extended-release tacrolimus and prednisone for 3 months and combination therapy of low dose sirolimus and extended-release tacrolimus thereafter for up to 3 years after liver transplantation Continue Advagraf (5-10 ng/ml) and 7.5 mg prednison; lower or discontinue steroids after day 180 at the discretion of the treating physician Conversion to sirolimus (3-5 ng/ml) and decrease Advagraf (3-5 ng/ml); 7.5 mg prednisone and lower or discontinue steroids after day 180 at the discretion of the treating physician</description>
    <arm_group_label>combination Tacrolimus and Sirolimus</arm_group_label>
    <other_name>Advagraf [Astellas Pharma bv)</other_name>
    <other_name>Rapamune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Patient received standard-dose of Tracrolimus Advagraf (5-10 ng/ml) and 7.5 mg prednison; lower or discontinue steroids after day 180 at the discretion of the treating physician</description>
    <arm_group_label>Tacrolimus</arm_group_label>
    <other_name>Advagraf</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Primary liver transplantation or retransplantation within 14 days after first&#xD;
             transplantation&#xD;
&#xD;
          -  Use of Advagraf at least 2 weeks prior to randomization&#xD;
&#xD;
          -  Patent hepatic artery&#xD;
&#xD;
          -  Closed abdominal wound&#xD;
&#xD;
          -  Stable graft function&#xD;
&#xD;
          -  Positive informed consent at time of randomization&#xD;
&#xD;
          -  Age 18-70 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with investigational drugs within 3 months before start of therapy&#xD;
&#xD;
          -  Multi organ transplantation&#xD;
&#xD;
          -  cGFR &lt; 30 ml/min&#xD;
&#xD;
          -  Proteinuria &gt; 800 mg/24 h&#xD;
&#xD;
          -  Hyperlipidemia refractory to optimal medical management (Cholesterol &gt; 9 mmol/l and/or&#xD;
             triglycerides &gt; 8.5 mmol/l). Patients with controlled hyperlipidemia are acceptable at&#xD;
             the time of randomization.&#xD;
&#xD;
          -  Known hypersensitivity to sirolimus or its derivatives&#xD;
&#xD;
          -  Thrombocytes &lt; 50 x 109 /L&#xD;
&#xD;
          -  Leukocytes &lt; 2.5 x 109 /L&#xD;
&#xD;
          -  Haemoglobin &lt; 6 mmol/L&#xD;
&#xD;
          -  Biopsy proven rejection 2 weeks prior to randomization&#xD;
&#xD;
          -  HIV positivity&#xD;
&#xD;
          -  Signs of recurrent or de novo cancer&#xD;
&#xD;
          -  Patients with non-HCC malignancies within the past 5 years (excluding successfully&#xD;
             treated squamous cell carcinoma and basal cell carcinoma of the skin)&#xD;
&#xD;
          -  Evidence of significant local or systemic infection&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  Women of child-bearing potential not willing to take oral contraception&#xD;
&#xD;
          -  Any other condition which in the opinion of the investigator would make the patient&#xD;
             unsuitable for enrollment, or could interfere with the patient participating in and&#xD;
             completing the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Herold J Metselaar, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UMCG</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LUMC</name>
      <address>
        <city>Leiden</city>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 27, 2013</study_first_submitted>
  <study_first_submitted_qc>October 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2013</study_first_posted>
  <last_update_submitted>August 19, 2021</last_update_submitted>
  <last_update_submitted_qc>August 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Liver transplantation long term renal function</keyword>
  <keyword>tacrolimus sirolimus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

